B-cell Acute Lymphoblastic Leukemia (B-ALL), Safety and Efficacy of CD19 UCAR-T Cells
Conditions
Brief summary
This is a single arm, open-label, single center, exploratory clinical study to evaluate the safety and efficacy of CD19 UCAR-T Cells in Patients With CD19+ B-cell acute lymphoblastic leukemia (B-ALL).
Detailed description
This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
Interventions
BIOLOGICALCD19 UCARTcells
This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
Sponsors
Shanghai Longyao Biotechnology Inc., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Subjects between 6 and 70 years of age, inclusive. * 2\. Subjects diagnosed as relapsed or refractory B cell acute lymphocytic leukemia (B-ALL): 1. Relapse as defined by 2nd or greater BM relapse or Any BM relapse after allogeneic SCT, naive lymphocytes in BM≥5%； 2. refractory as defined by not achieving a CR after 2 rounds of standard chemotherapy. * 3\. Life expectancy \> 12 weeks. * 4\. ECOG score between 0 and 1. * 5\. Liver, Renal, Heart and Lungs function defined as: 1. Creatininec≤1.5 ULN; 2. ALT/AST ≤2.5 ULN; 3. Total Bilirubin≤1.5×ULN; 4. Pulse oxygenation≥92%; 5. Left Ventricular Shortening Fraction (LVSF)≥50%; * 6\. Subjects could comprehend the clinical study and able to provide written consent at the time of consent or assent.
Exclusion criteria
* 1\. Pregnant or lactating women, or men or women with pregnancy plans within 6 months. * 2\. Subjects with contagious disease，such as HIV, active HBV and HCV, and syphilis, etc. * 3\. Subjects with mental or psychological illness who cannot be combined with treatment and efficacy evaluation. * 4\. Subjects with severe autoimmune disease and long-term use of immunosuppressants. * 5\. Subjects with active or uncontrollable infections requiring systemic treatment within 14 days prior to enrollment. * 6\. Subjects with any unstable systemic disease including, but not limited to, active infection (except for local infection), unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] classification ≥ III). * 7\. subjects combined with dysfunction of vital organs such as lung, brain and kidney. * 8\. subjects that Participated in other similar clinical trials within 6 months. * 9\. subjects currently receiving treatment for other gene therapy. * 10\. subjects combined with graft versus host disease (GVHD). * 11\. Other subjects judged by the researchers to be unsuitable for admission to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Adverse events (AEs) | 24 weeks | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 |
| Graft-versus-Host Disease (GVHD) | 42 days | Number of Participants with the GVHD by monitoring the epithelial cell damage in target organs including skin, liver, and gastrointestinal tract. |
| Expression of CD19 UCART cells | 2 years | Expression of CD19 UCART cells detected by flow cytometry in blood and bone marrow. |
| Detection of CD19 UCART cells | 2 years | Detection of CD19 UCART cells in blood, bone marrow by Quantitative Polymerase Chain Reaction (q-PCR). |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | 2 years |
| Overall Remission Rate (ORR) | 2 years |
| Disease-free survival (DFS) | 2 years |
| Progression-free survival (PFS) | 2 years |
| Complete Remission (CR) | 2 years |
| Disease Stabilization (SD) | 2 years |
| Disease Progression (PD) | 2 years |
Countries
China
Contacts
Primary ContactTengfeng Ni, Master
Outcome results
None listed